Form 4 for CUE Cue Biopharma, Inc.
Accepted 2026-08-03 16:19:19 ET · period of report 2026-07-30 · accession 0001320383-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-03 16:19 | 2026-07-30 | CUE | Ahlers James M | CFO | A - Grant | $0.00 | +25.5K | 25.5K | New | $0 |
| D | 2026-08-03 16:19 | 2026-07-30 | CUE | Ahlers James M | CFO | A - Grant | $0.00 | +51.0K | 51.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-30 | A | A | 25,500 | $0.00 | 25,500 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-07-30 | A | A | 51,000 | $0.00 | 51,000 | D | $30.40 · — to 2036-07-30 | 51,000 Common Stock | (F2) The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date. |